RESEARCH ARTICLE


Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update



Alejandro López-Requenaa, b, Oscar R. Burrone*, b
a Department of Antibody Engineering, Center of Molecular Immunology, P.O. Box 16040, Havana 11600, Cuba
b Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 173
Abstract HTML Views: 548
PDF Downloads: 236
Total Views/Downloads: 957
Unique Statistics:

Full-Text HTML Views: 130
Abstract HTML Views: 394
PDF Downloads: 152
Total Views/Downloads: 676



© 2009 LÓpez-Requena and Burrone;

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy; E-mail: burrone@icgeb.org


Abstract

The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation. One major challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells. We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas. Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed.

Keywords: Anti-Idiotypic Antibodies, NeuGc, Ganglioside, Idiotype, B Cell Lymphoma.